

ASX Announcement

10 September 2026

Clarification of BCAL's position in relation to Genetic Signatures (ASX:GSS)

BCAL Diagnostics Limited (ASX: BDY) (BCAL or the Company) refers to the article published in *The Australian Financial Review's* Street Talk column on 10 September 2026 headed "Three's a party! Medtech BCAL woos Genetic Signatures, Sonic's Microba" (the Article).

BCAL's position in relation to Genetic Signatures Limited (ASX: GSS) (Genetic Signatures) is unchanged and is as set out in the Company's announcements dated 03 September 2026, 26 August 2026 and 02 July 2026.

As previously announced, BCAL holds a relevant interest in approximately 18.46% of the issued shares of Genetic Signatures and has requested a general meeting of Genetic Signatures under section 249D of the *Corporations Act 2001* (Cth) to consider resolutions to appoint two directors of Genetic Signatures and remove a director. BCAL's interest in Genetic Signatures is to assess potential technology synergies and collaboration opportunities that could strengthen our respective platforms and create additional value.

BCAL confirms that, as at the date of this announcement, it has not made or received any proposal in relation to and is not in discussions with Genetic Signatures or Microba Life Sciences Limited (ASX: MAP) (Microba) regarding, a merger or other combination of BCAL, Genetic Signatures and Microba. No such proposal has been considered by the BCAL Board.

The comments attributed in the Article to Mr David Williams of Kidder Williams, which advises BCAL in relation to its investment in Genetic Signatures, refer to the views of some fund managers who have been advocating for a three-way merger. These comments were not made on behalf of, or with the authority of BCAL.

BCAL believes scale is important to the long-term success of Australian diagnostics companies. Consistent with that view, BCAL continues to assess opportunities that it considers may create value for its shareholders.

Nothing in this announcement should be taken as precluding BCAL from consideration of any proposal or transaction in the future

This announcement has been authorised for release by the Board of BCAL Diagnostics Limited.

ENDS

For further information:

Anne-Louise Arnett

Chief Executive Officer

aarnett@bcaldiagnostics.com

Jayne Shaw

Executive Chair

jshaw@bcaldiagnostics.com

For personal use only

About BCAL Diagnostics

BCAL is an Australian company engaged in early cancer detection. BCAL launched its first test BREASTEST*plus*™ as a 'rule-out' test designed to be used in the clinical evaluation of breast disease for women with dense breasts. This is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health.

BCAL also holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

BCAL is headquartered in Sydney, Australia and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.